User:Mr. Ibrahem/Oxybutynin

Mr. Ibrahem/Oxybutynin
Clinical data
Trade names	Ditropan, others
AHFS/Drugs.com	Monograph
MedlinePlus	a682141
License data	EU EMA: by INN;
Pregnancy; category	AU: B1; ;
Antimuscarinic
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only and OTC;
Pharmacokinetic data
Protein binding	91–93%
Elimination half-life	12.4–13.2 hours
Identifiers
	IUPAC name 4-Diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylethanoate;
Chemical and physical data
JSmol)	Interactive image;
	SMILES O=C(OCC#CCN(CC)CC)C(O)(c1ccccc1)C2CCCCC2;
	InChI InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3 ; Key:XIQVNETUBQGFHX-UHFFFAOYSA-N ;
	(verify)

Oxybutynin, sold as under the brand names Ditropan among others, is a medication used to treat

applied to the skin.^[1]

Common side effects include

antimuscarinic and works by blocking the effects of acetylcholine on smooth muscle.^[1]

Oxybutynin was approved for medical use in the United States in 1975.

NHS less than GB£3 per month as of 2019.^[5] In the United States the wholesale cost of this amount is about US$14.^[6] In 2017, it was the 100th most commonly prescribed medication in the United States, with more than seven million prescriptions.^[7]^[8]

References

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Oxybutynin Chloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 24 June 2019. Retrieved 3 March 2019.
^ ^a ^b "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 31 October 2020. Retrieved 6 September 2020.
^ "Oxybutynin Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
ISBN 978-0-7020-7442-4. Archived
from the original on 2021-05-22. Retrieved 2021-11-09.

ISBN 9780857113382
.

^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.

^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.

^ "Oxybutynin - Drug Usage Statistics". ClinCalc. Archived from the original on 2 July 2020. Retrieved 11 April 2020.

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Oxybutynin&oldid=1078351271"

[AHFS2019-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Oxybutynin Chloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 24 June 2019. Retrieved 3 March 2019.

[WHO2020DDD-2] "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 31 October 2020. Retrieved 6 September 2020.

[Preg2019-3] "Oxybutynin Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 6 March 2019. Retrieved 3 March 2019.

[Hitch2019-4] ISBN 978-0-7020-7442-4. Archived
from the original on 2021-05-22. Retrieved 2021-11-09.

[BNF76-5] ISBN 9780857113382
.

[NADAC2019-6] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[ref-7] "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.

[ref1-8] "Oxybutynin - Drug Usage Statistics". ClinCalc. Archived from the original on 2 July 2020. Retrieved 11 April 2020.

[1]

[5]

[6]

[7]

[8]